Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

277
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
277
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.0K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment inequity among older adults with newly diagnosed acute myeloid leukemia ineligible for intensive therapy.

Leukemia & lymphoma·2026
Same author

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

Blood cancer journal·2026
Same author

Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS).

HemaSphere·2026
Same author

Menin inhibitors for patients with relapsed/refractory acute myeloid leukemia (AML): a systematic review and meta-analysis.

Leukemia & lymphoma·2026
Same author

Hematologic Responses Achieved with Luspatercept in Higher-Risk Myelodysplastic Syndromes.

Blood advances·2026
Same author

Desmosine as a Novel Biomarker Candidate for Pulmonary and Cutaneous Chronic Graft-Versus-Host Disease.

Transplantation and cellular therapy·2026

Related Experiment Video

Updated: Jun 2, 2025

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.7K

How I treat higher-risk MDS.

Alain Mina1, Rami Komrokji2

  • 1Myeloid Malignancies Program, Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD.

Blood
|January 14, 2025
PubMed
Summary

This review discusses higher-risk myelodysplastic syndromes (MDS), focusing on updated classifications and prognostication tools. It highlights the importance of integrating genetic mutations alongside traditional scoring systems for better patient management.

More Related Videos

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.1K
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

11.5K

Related Experiment Videos

Last Updated: Jun 2, 2025

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.7K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.1K
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

11.5K

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Myelodysplastic syndromes (MDS) are heterogeneous myeloid malignancies with defective hematopoiesis.
  • Current International Prognostic Scoring Systems (IPSS) rely on clinical, morphological, and cytogenetic data.
  • Higher-risk MDS management aims to delay leukemic transformation and prolong survival, with hypomethylating agents and stem cell transplantation as standards of care.

Purpose of the Study:

  • To review the approach to higher-risk myelodysplastic syndromes (MDS).
  • To incorporate updated classifications and novel prognostication tools, including genomic features.
  • To illustrate clinical case examples and share insights from recent clinical trials.

Main Methods:

  • Review of current literature and clinical trial data.
  • Analysis of updated MDS classification systems.
  • Integration of genetic mutation data into prognostication.

Main Results:

  • Traditional IPSS lacks comprehensive prognostic value due to >80% of MDS cases having somatic mutations.
  • Genomic features are crucial for prognostication, leading to the development of molecular IPSS.
  • Updated classifications and molecular data enhance risk stratification for higher-risk MDS.

Conclusions:

  • A revised approach to higher-risk MDS is necessary, integrating molecular data with clinical and cytogenetic features.
  • New prognostication tools and classifications improve the management of patients with myelodysplastic syndromes.
  • Lessons learned from clinical trials inform future therapeutic strategies for MDS.